Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

• Published in: Journal of blood medicine Vol. 7; no. Issue 1; pp. 1 - 4
• Main Authors: Nomura, Shosaku, Maeda, Yoshinobu, Ishii, Kazuyoshi, Katayama, Yuta, Yagi, Hideo, Fujishima, Naoto, Ota, Shuichi, Moriyama, Masato, Ikezoe, Takayuki, Miyazaki, Yasuhiko, Hayashi, Kunio, Fujita, Shinya, Satake, Atsushi, Ito, Tomoki, Kyo, Taiichi, Tanimoto, Mitsune
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2016; Taylor & Francis Ltd; Dove Medical Press
• Subjects: aHSCT; Anticoagulants; Biomarkers; Bone marrow; Cyclophosphamide; Disease; Dosage and administration; Fibrinolytic agents; Hematology; Hematopoietic stem cell transplantation; HMGB1; Hospitals; Leukemia; Original Research; PAI-1; Patients; Proteins; Radiotherapy; Standard deviation; Stem cells; TBI; transplantation-associated coagulopathy; Transplants & implants; Variance analysis; Japan; PAI-1; TBI; HMGB1; transplantation-associated coagulopathy; aHSCT
• ISSN: 1179-2736; 1179-2736
• DOI: 10.2147/jbm.s93008

Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.